Biocon gets approval for diabetes drug Liraglutide in India

03 Jun 2025 Evaluate

Biocon has received approval in India for its Liraglutide drug substance, and its wholly owned subsidiary -- Biocon Pharma, has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India, CDSCO (Central Drugs Standard Control Organisation).

The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise. The approval was received from the CDSCO under the recently formulated 101 route that enables recognition of approvals granted by established and referenced serious regulatory authorities.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

392.80 4.55 (1.17%)
05-Dec-2025 15:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.00
Dr. Reddys Lab 1276.55
Cipla 1520.55
Zydus Lifesciences 933.10
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×